ISSN: 2538-2462
January 2023
Vol. 8 No. 1 (2023)
Evaluation of the Neuroprotective Effect of Chalcone on P53 and Caspase III Expression and D2-Like Dopaminergic Receptor Up-Regulation in vitro Parkinson's Model
Journal of Cellular & Molecular Anesthesia,
Vol. 8 No. 1 (2023),
,
Page 3-11
https://doi.org/10.22037/jcma.v8i1.38877
Abstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder of the central nervous system (CNS). Several studies indicated abnormal cell death in neurodegenerative diseases. Chalcone is a compound of natural origin with various properties such as antioxidant, anti-inflammatory, and inhibition of apoptosis. We investigated the impact of chalcone in an in-vitro model of PD.
Materials and Methods: PC12 cells were divided into four groups. Negative control, 6-hydroxy dopamine (6-OHDA) group (treatment with 75µM 6-OHDA), sham (treated with dimethyl sulfoxide), and the experimental groups with different dosages of chalcone treatment. Cell viability and reactive oxygen species (ROS) were assessed by MTT and ROS kit, respectively. The expressions of D2-like receptors, P53, and caspase III were evaluated by Western blotting.
Results: We found that 6-OHDA induced cytotoxicity and ROS production. The viability results showed that all doses of chalcone significantly increased viability after 48 hours compared to the control group (P<0.01). The western blotting results showed that caspase III and P53 expression decreased significantly in the experimental groups compared to the 6-OHDA group. However, D2-like receptor expression did not significantly differ between the experimental and the 6-OHDA group.
Conclusion: Complementary therapies, such as the use of antioxidants and the chalcone family, along with standard treatments for neurodegenerative diseases such as Parkinson's, may reduce the symptoms of the disease.
- Chalcone
- Dopaminergic Receptors
- Apoptosis
- Parkinson’s Disease
How to Cite
References
Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002;55(1):25-31.
Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci. 2009;30(1):41-7.
Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143-51.
Che Mat Zubaidi S, Halim S, Kasini ZM, Fazleen NE, Thiruselvam V, Rajagopal V. Red Palm Oil Prevents Congestive Impairment In A Rat Model Of D-Galactose-Induced Aging. J Cell Mol Anesth. 2021;6(4):294-305.
Chiu CH, Weng SJ, Yeh SH, Jhao YT, Chang HF, Huang WS, et al. Assessment of the anti-nociceptive effects of fetal ventral mesencephalic tissue allografts in a rat model of hemi-Parkinson's disease using fMRI. Front Aging Neurosci. 2022;14:948848.
Lee FJ, Liu F. Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res Rev. 2008;58(2):354-64.
Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. Int J Mol Sci. 2021;22(9).
Darabi S, Noori-Zadeh A, Rajaei F, Abbaszadeh HA, Bakhtiyari S, Roozbahany NA. SMER28 Attenuates Dopaminergic Toxicity Mediated by 6-Hydroxydopamine in the Rats via Modulating Oxidative Burdens and Autophagy-Related Parameters. Neurochem Res. 2018;43(12):2313-23.
Rubin JE, McIntyre CC, Turner RS, Wichmann T. Basal ganglia activity patterns in parkinsonism and computational modeling of their downstream effects. Eur J Neurosci. 2012;36(2):2213-28.
Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, et al. Treatment strategies for Parkinson's disease. Neurosci Bull. 2010;26(1):66-76.
Stoker TB, Barker RA. Recent developments in the treatment of Parkinson's Disease. F1000Res. 2020;9.
Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism Relat Disord. 2016;31:3-13.
Bohnen NI, Albin RL, Müller ML, Chou K. Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease. US Neurol. 2011;7(2):100-8.
Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157-65.
Constantinescu T, Lungu CN. Anticancer Activity of Natural and Synthetic Chalcones. Int J Mol Sci. 2021;22(21).
Maliyakkal N, Saleem U, Anwar F, Shah MA, Ahmad B, Umer F, et al. Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson's diseases. Environ Sci Pollut Res Int. 2022;29(5):7271-82.
Constantinescu T, Mihis AG. Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones. Int J Mol Sci. 2022;23(19).
Królicka E, Kieć-Kononowicz K, Łażewska D. Chalcones as Potential Ligands for the Treatment of Parkinson's Disease. Pharmaceuticals (Basel). 2022;15(7).
Ouyang Y, Li J, Chen X, Fu X, Sun S, Wu Q. Chalcone Derivatives: Role in Anticancer Therapy. Biomolecules. 2021;11(6).
Moreira J, Almeida J, Saraiva L, Cidade H, Pinto M. Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness. Molecules. 2021;26(12).
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5.
Porritt M, Stanic D, Finkelstein D, Batchelor P, Lockhart S, Hughes A, et al. Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord. 2005;20(7):810-8.
Gröger A, Kolb R, Schäfer R, Klose U. Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLoS One. 2014;9(1):e84081.
Bjørklund G, Peana M, Maes M, Dadar M, Severin B. The glutathione system in Parkinson's disease and its progression. Neurosci Biobehav Rev. 2021;120:470-8.
Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC, et al. Plasma levels of lipid peroxides in patients with Parkinson's disease. Eur Rev Med Pharmacol Sci. 2009;13(2):129-32.
Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res. 2007;85(5):919-34.
Liu Y, Guo Y, An S, Kuang Y, He X, Ma H, et al. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PLoS One. 2013;8(5):e62905.
Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74(4):418-25.
Roslan N, Shariff H. Potential Pharmacotherapy of Olea Europaea (Olive) Fruit Oil Against Neurotoxicity Induced Methamphetamine. J Cell Mol Anesth. 2019;4(2):67-8.
Ismail U, Mohamad Shariff M. Potential Therapeutic Effects of Olea Europaea (Olive) Fruit Oil as neuroprotective agent against neurotocixity induced opioid. J Cell Mol Anesth. 2019;3(4):159.
Pérez-González A, Castañeda-Arriaga R, Guzmán-López EG, Hernández-Ayala LF, Galano A. Chalcone Derivatives with a High Potential as Multifunctional Antioxidant Neuroprotectors. ACS Omega. 2022;7(43):38254-68.
Kachadourian R, Day BJ, Pugazhenti S, Franklin CC, Genoux-Bastide E, Mahaffey G, et al. A synthetic chalcone as a potent inducer of glutathione biosynthesis. J Med Chem. 2012;55(3):1382-8.
Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, Iyengar S, et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J 2007;21(9):2226-36.
González R, Ballester I, López-Posadas R, Suárez MD, Zarzuelo A, Martínez-Augustin O, et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr. 2011;51(4):331-62.
Amanollahi M, Jameie M, Heidari A, Rezaei N. The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases. Mol Neurobiol. 2022.
Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. Nutrients. 2018;10(11).
Lee OH, Lee BY. Antioxidant and antimicrobial activities of individual and combined phenolics in Olea europaea leaf extract. Bioresour Technol. 2010;101(10):3751-4.
Mendrysa SM, Ghassemifar S, Malek R. p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer. 2011;2(4):431-42.
Pemberton JM, Pogmore JP, Andrews DW. Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins. Cell Death Differ. 2021;28(1):108-22.
Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-8.
Nair VD, McNaught KS, González-Maeso J, Sealfon SC, Olanow CW. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem. 2006;281(51):39550-60.
Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis. 2009;14(4):478-500.
- Abstract Viewed: 87 times
- PDF Downloaded: 44 times
